| Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ... New England Journal of Medicine 377 (20), 1919-1929, 2017 | 4271 | 2017 |
| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2736 | 2018 |
| Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, ... Journal of Clinical Oncology 40 (12), 1301-1311, 2022 | 782 | 2022 |
| Effects of cigarette smoking on reproduction C Dechanet, T Anahory, JC Mathieu Daude, X Quantin, L Reyftmann, ... Human reproduction update 17 (1), 76-95, 2011 | 465 | 2011 |
| Bevacizumab in patients with nonsquamous non–small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study B Besse, S Le Moulec, J Mazières, H Senellart, F Barlesi, C Chouaid, ... Clinical Cancer Research 21 (8), 1896-1903, 2015 | 249 | 2015 |
| Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients JL Pujol, JM Boher, J Grenier, X Quantin Lung cancer 31 (2-3), 221-231, 2001 | 232 | 2001 |
| Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of … JL Pujol, JP Daures, A Riviere, E Quoix, V Westeel, X Quantin, JL Breton, ... Journal of the National Cancer Institute 93 (4), 300-308, 2001 | 188 | 2001 |
| Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin JL Pujol, JL Breton, R Gervais, P Rebattu, A Depierre, JF Morère, ... Annals of oncology 16 (4), 602-610, 2005 | 179 | 2005 |
| Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer JL Pujol, X Quantin, W Jacot, JM Boher, J Grenier, PJ Lamy Lung Cancer 39 (2), 131-138, 2003 | 150 | 2003 |
| Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations J Mazieres, C Cropet, L Montané, F Barlesi, PJ Souquet, X Quantin, ... Annals of Oncology 31 (2), 289-294, 2020 | 147 | 2020 |
| Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data D Choma, JP Daures, X Quantin, JL Pujol British journal of cancer 85 (1), 14-22, 2001 | 136 | 2001 |
| Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial. DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, LG Paz-Ares, ... Journal of Clinical Oncology 39 (15_suppl), 8511-8511, 2021 | 123 | 2021 |
| FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration … I Solassol, F Pinguet, X Quantin Biomolecules 9 (11), 668, 2019 | 120 | 2019 |
| Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. JL Pujol, J Grenier, E Parrat, M Lehmann, T Lafontaine, X Quantin, ... American journal of respiratory and critical care medicine 154 (3), 725-733, 1996 | 114 | 1996 |
| Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors W Jacot, X Quantin, JM Boher, F Andre, L Moreau, M Gainet, A Depierre, ... British journal of cancer 84 (7), 903-909, 2001 | 101 | 2001 |
| Systemic therapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort CM Du Vignaux, E Dansin, L Mhanna, L Greillier, E Pichon, M Kerjouan, ... Journal of Thoracic Oncology 13 (11), 1762-1770, 2018 | 74 | 2018 |
| Neutrophils in the era of immune checkpoint blockade J Faget, S Peters, X Quantin, E Meylan, N Bonnefoy Journal for ImmunoTherapy of Cancer 9 (7), 2021 | 70 | 2021 |
| Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. P Ray, X Quantin, J Grenier, JL Pujol Cancer detection and prevention 22 (4), 293-304, 1998 | 68 | 1998 |
| Concomitant brain radiotherapy and vinorelbine–ifosfamide–cisplatin chemotherapy in brain metastases of non-small cell lung cancer X Quantin, F Khial, M Reme-Saumon, FB Michel, JL Pujol Lung Cancer 26 (1), 35-39, 1999 | 54 | 1999 |
| Programmed cell death ligand 1-expressing circulating tumor cells: a new prognostic biomarker in non-small cell lung cancer L Sinoquet, W Jacot, L Gauthier, S Pouderoux, M Viala, L Cayrefourcq, ... Clinical Chemistry 67 (11), 1503-1512, 2021 | 53 | 2021 |
